相关实验视频

Updated: May 21, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

纳米颗粒通过破坏细胞循环分布来减弱视网膜病理血管生成

Zheng Nie¹, Yongxuan Liu¹, Li Xu²

¹Department of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.

Nanomedicine (London, England)

|March 21, 2025

概括

纳米粒子 (SeNPs) 通过影响血管内皮细胞增殖,有效抑制视网膜新血管化. 这项研究表明,SeNPs是治疗病态视网膜新血管化的有前途的新疗法.

科学领域:

眼科医生眼科眼科
纳米医学是一种纳米医学.
细胞生物学细胞生物学

背景情况:

病理性视网膜新血管化 (RNV) 是视力丧失的主要原因.
目前对RNV的治疗有局限性,需要开发新的治疗策略.
纳米粒子 (SeNPs) 由于其独特的特性,已成为潜在的治疗剂.

研究的目的:

研究纳米颗粒 (SeNPs) 抑制视网膜新血管化 (RNV) 的机制.
评估SeNPs作为病理性RNV的潜在治疗方法的疗效.
为了确定RNV干预的新型治疗点.

主要方法:

合成的SeNP的表征和识别.
在人静脉内皮细胞 (HUVEC) 的体外和体内研究以及氧气诱导视网膜病变的小鼠模型.
细胞增殖的评估使用三标记的胺.
流细胞计,免疫光学和西部涂抹以阐明分子机制.

主要成果:

在体外和体内,SeNPs显著抑制了血管内皮细胞的增殖.
通过PI3K-AKT-p21轴,SeNP调节细胞周期相关的蛋白质表达.
观察到细胞周期从G1到S阶段过渡的抑制.

结论:

显著的SENPs显示出对视网膜新血管化的显著抑制作用.
该机制涉及PI3K-AKT-p21通路的调节,影响细胞周期进展.
对于治疗病理性RNV而言,SeNPs是一个有前途的新疗法.

关键词:

纳米粒子是一种纳米粒子.血管新生的产生.氧气诱导的视网膜病变视网膜新血管化疗法细胞循环中的细胞循环.

更多相关视频

Retinal Explant of the Adult Mouse Retina as an Ex Vivo Model for Studying Retinal Neurovascular Diseases

Retinal Explant of the Adult Mouse Retina as an Ex Vivo Model for Studying Retinal Neurovascular Diseases

Published on: December 9, 2022

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...